AustinPx

AustinPx is a fee-for-service CDMO founded in 2007, based in Georgetown, Texas. The company specializes in formulation development, analytical services, and GMP manufacturing of oral dosage forms from preclinical through Phase II clinical stages.

Core Capabilities:

• Preclinical development and formulation development
• Analytical method development and characterization
• GMP manufacturing for oral formulations and dose forms
• Bioavailability enhancement strategies
• Speed-to-clinic and market development strategies

Proprietary Technology: AustinPx is the inventor of KinetiSol™ Technology, a next-generation amorphous solid dispersion (ASD) platform designed for poorly soluble active pharmaceutical ingredients. The technology offers a smaller footprint, broader design space, and greener processing solutions compared to conventional ASD approaches. The company can supply KinetiSol drug product intermediate (DPI) through commercial manufacturing.

Service Scope: The cGMP facility can supply oral formulations and dose forms for preclinical testing, GLP toxicology studies, and Phase I/II clinical studies. The company emphasizes a data-driven, technology-agnostic approach where formulation strategy is tailored to the unique physicochemical characteristics of each molecule and client goals. AustinPx positions itself as client-centric, with flexible and responsive systems designed for the fast-paced early development environment.